6461.TWO Intech Biopharm Ltd

Healthcare Biotechnology Taiwan OTC Exchange
26.70 TWD
Close of Nov 6, 2026
14.10 30.00
Market cap
TWD 1.82B
P/E
-
P/B
2.11x
ROE
-48.0%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is 6461.TWO undervalued?

Graham number

The Graham number of Intech Biopharm Ltd cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Intech Biopharm Ltd fundamental analysis

No fundamental analysis for Intech Biopharm Ltd yet.

Intech Biopharm Ltd stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Intech Biopharm Ltd

Intech Biopharm Corporation engages in developing and manufacturing generic drugs to treat respiratory diseases in Taiwan and internationally. The company offers combinations, formulations, and generic drugs for the treatment of respiratory diseases using technology platforms, such as inhaled low ethanol formulation, a metered dose inhaler platform for treating asthma and COPD, as well as dry powder inhaler that comprises blisters and capsules. Its products include SYN006, S…

Full company profile